Lunsekimig (anti-IL-13/anti-TSLP) is a nanobody that blocks both IL-13 and TSLP and is currently included in a phase II clinical trial for moderate-to-severe asthma (AIRCULES) [63]. Here, IL13 is linked to asthma.